Sphenopalatine ganglion block for refractory COVID-19 headache: a descriptive case series.
Braz J Anesthesiol
; 71(6): 667-669, 2021.
Article
in English
| MEDLINE | ID: covidwho-1210112
ABSTRACT
Coronavirus SARS-CoV-2 is responsible for the COVID-19 pandemic, and headache is reported in 6.5% to 34% of all cases. There is little published evidence on the pharmacological treatment of COVID-19 headache. This case series presents six COVID-19 infected patients with refractory headache in which intranasal bedside Sphenopalatine Ganglion Block was performed for analgesia. All patients had a reduction in headache intensity from severe to mild or no pain after the procedure with minor transient side effects. Proposed mechanisms of action include reduction of local autonomic stimuli, intracranial vasoconstriction, and reduction of vasoactive substances release in the pterygopalatine fossa.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Sphenopalatine Ganglion Block
/
COVID-19
Type of study:
Case report
Limits:
Humans
Language:
English
Journal:
Braz J Anesthesiol
Year:
2021
Document Type:
Article
Affiliation country:
J.bjane.2021.04.024
Similar
MEDLINE
...
LILACS
LIS